Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934697 · ClinicalTrials.gov registry record · NA
Imaginal Exposure II Study: In-Vivo
A NA study, sponsored by University of Louisville.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT03934697: Completed NA study, sponsored by University of Louisville.
NCT03934697 is a NA study that has completed, run by University of Louisville. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03934697, a NA study, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to test if imaginal exposure therapy can decrease symptoms of eating disorders and anxiety.
Primary Outcome
The EDE-Q is a 41-item self-report questionnaire version of the Eating Disorder Examination, which is a semi-structured interview designed to assess eating disorders symptom frequency and severity over the past 28 days. The EDE-Q uses a 7-point forced-choice rating scheme (No days; 1-5 days; 6-12 days; 13-15 days; 16-22 days; 23-27 days; Everyday). The EDE-Q has four subscales with the question stem "How many days out of the past 28 days...": Restraint (e.g. Have you been consciously trying to r
Interventions
- BEHAVIORAL imaginal exposure therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2022-10-01 |
| Phase | NA |
What the finished NCT03934697 record still lists
NCT03934697 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which imaginal exposure therapy is the first listed.
NCT03934697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03934697 about?
NCT03934697 is a clinical study titled "Imaginal Exposure II Study: In-Vivo". The purpose of this study is to test if imaginal exposure therapy can decrease symptoms of eating disorders and anxiety.
What is the current status of trial NCT03934697?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2017-05-01. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT03934697?
The interventions under investigation include: imaginal exposure therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03934697?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03934697's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI